AccScience Publishing / AN / Volume 2 / Issue 2 / DOI: 10.36922/an.378
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Myographic evidence of polymyositis and dermatomyositis in COVID-19 patients

Nareen Haikaz Hasrat1 Haithem Jawad Kadhum1 Zaineb Adil Yakob1 Ali Raheem Hashim2 Hassan Ala Farid3*
Show Less
1 Department of Physiology, College of Medicine, University of Basrah, Basrah, Iraq
2 Department of Medicine, College of Medicine, University of Basrah, Basrah, Iraq
3 Institute of Medical and Biomedical Education, St. George’s University of London, London, United Kingdom
Advanced Neurology 2023, 2(2), 378
Submitted: 15 February 2023 | Accepted: 2 May 2023 | Published: 25 May 2023
© 2023 by the Author(s). Licensee AccScience Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Idiopathic inflammatory myopathies, commonly known as myositis, are a diverse group of disorders defined clinically by persistent muscle weakness and reduced muscle endurance, as well as inflammatory cell infiltrates inside the muscle tissue. Myositis as a complication of coronavirus disease 2019 (COVID-19) has been described in an increasing number of reports. An analytical and cross-sectional study was undertaken in Basrah to analyze nerve conduction studies (NCS) and electromyographic (EMG) data in a COVID-19-affected patient. During the evaluation of 2240 patients, three cases of myositis were reported among the COVID-19 population, two of them with new clinical and EMG evidence of inflammatory myositis after the onset of COVID-19 infection, and one patient had a history of polymyositis before the COVID-19 pandemic, but a relapse was triggered by COVID-19, resulting in respiratory failure and death. The study found that the prevalence of myositis among the COVID-19 population was equal to 0.22%, which is 44 times higher than the prevalence of myositis (0.005%) worldwide before the onset of COVID-19 (P < 0.001).

Inflammatory myopathy
  1. Hashim AR, Kadhum HJ, Farid HA, 2022, The pattern of Covid 19 among hospitalized athletics patient: A comparative study from Basrah city, Southern Iraq. J Res Med Dent Sci, 10: 36–40.


  1. Farid HA, Hashim AR, Hasrat NH, et al., 2021, The neurological manifestations of COVID-19 and their relationship with the disease severity in hospitalized patients: A single-centered, cross-sectional study on patients with COVID-19 from Basra, Iraq. Multicult Educ, 7: 391.


  1. Hasrat NH, Kadhum HJ, Hashim AR, et al., 2022, Neurographic evidence of inflammatory polyneuropathies in Peri-COVID-19 circumstances and their relationship with acute disease severity and inflammatory storm. Cureus, 14: e23517.


  1. Lundberg IE, Miller FW, Tjärnlund A, et al., 2016, Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med, 280: 39–51.


  1. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al., 2020. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology, 95: e1060–e1070.


  1. Taga A, Lauria G, 2022, COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era. J Peripher Nerv Syst, 27: 4–30.


  1. Hasrat NH, Kadhum HJ, Hashim AR, et al., 2022, Neurophysiological changes by nerve conduction study and electromyography in acute and long-term COVID-19 circumstances: A comparative study protocol and review. J Xian Shiyou Univ, 18: 241–249.


  1. Case Definition for Coronavirus Disease, 2019, (COVID-19), as of 3 December 2020. European Centre for Disease Prevention and Control. Available from: https://www.ecdc. [Last accessed on 2022 Jun 12].


  1. Preston D, Shapiro B, 2020, Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations. 4th ed. Amsterdam: Elsevier Saunders. Available from: [Last accessed on 2022 Dec 10].


  1. Anthony S, Phrathep DD, El-Husari A, et al., 2022, Post- COVID-19 polymyositis: A case report. Cureus, 14: e30991. https://10.7759/cureus.30991


  1. Hunter K, Lyon MG, 2012, Evaluation and management of polymyositis. Indian J Dermatol, 57: 371–374.


  1. Gokhale Y, Patankar A, Holla U, et al., 2020, Dermatomyositis during COVID-19 pandemic (A case series): Is there a cause effect relationship? J Assoc Physicians India, 68: 20–24.


  1. Movahedi N, Ziaee V, 2021, COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr Rheumatol Online J, 19: 86.


  1. Saud A, Naveen R, Aggarwal R, et al., 2021, COVID-19 and myositis: What we know so far. Curr Rheumatol Rep, 23: 63.


  1. Naveen R, Sundaram TG, Agarwal V, et al., 2021, Teleconsultation experience with the idiopathic inflammatory myopathies: A prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int, 41: 67–76.


  1. Venalis P, Lundberg IE, 2014, Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford), 53: 397–405.


  1. Albakri AM, Subki AH, Albeity A, et al., 2022, Dermatomyositis flare after a COVID-19 infection successfully treated with rituximab: A case report and literature review. J Inflamm Res, 15: 6047–6053.


  1. Cheeti A, Brent LH, Panginikkod S, 2022, Autoimmune myopathies. In: StatPearls. Treasure Island, FL: StatPearls Publishing.


  1. Amin S, Rahim F, Noor M, et al., 2022, Polymyositis: The comet tail after COVID-19. Cureus, 14: e26453.


  1. Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G, 2021 New onset of autoimmune diseases following COVID-19 diagnosis. Cells, 10: 3592.


  1. Ochani R, Asad A, Yasmin F, et al., 2021, COVID-19 pandemic: From origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med, 29: 20–36.


  1. Anka AU, Tahir MI, Abubakar SD, et al., 2021, Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol, 93: e12998.


  1. Li YC, Bai WZ, Hashikawa T, 2020, The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol, 92: 552–555.


  1. Zubair AS, McAlpine LS, Gardin T, et al., 2020, Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurol, 77: 1018–1027.


  1. Canetta C, Accordino S, Buscarini E, et al., 2020, Syncope at SARS-CoV-2 onset. Auton Neurosci, 229: 102734.


  1. Batchu S, Diaz MJ, Tran JT, et al., 2023, Spatial mapping of genes implicated in SARS-CoV-2 neuroinvasion to dorsolateral prefrontal cortex gray matter. COVID, 3: 82–89.


  1. Sizemore G, Lucke-Wold B, Small C, 2022, Review of SARS-COV-2 systemic impact: Building the case for sepsis via virus in the circulatory system. SM J Neurol Disord Stroke, 6: 7.


  1. Small C, Mehkri Y, Panther E, et al., 2020, Coronavirus disease-2019 and stroke: Pathophysiology and management. Can J Neurol Sci, 28: 1–8.
Conflict of interest
The authors declare that they have no competing interests.
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: TBA, Published by AccScience Publishing